Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 159 participants.
Also called NCT02264288
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 159 participants
- Sponsor
- Celularity Incorporated
- Registry
-
NCT02264288
-
- Other papers using this trial's data
- Human Placenta-Derived Cells (PDA-002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi-Center, Randomised, Double-Blind, Placebo-Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT02264288. Randomized; triple masking; primary purpose treatment. Start 2014-10-23 (actual); primary completion 2018-02-27 (actual). Results posted on 2026-06-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.
- Acronym
- DFU-002
- Condition
- Peripheral Arterial Disease
- Condition
- Diabetic Foot
- Intervention (Biological)
- PDA-002
- Intervention (Other)
- Placebo
- Lead sponsor
- Celularity Incorporated
Record details
- Record id
cardio:ct-nct02264288- Content hash
9abf369dae421608f366345289d201d15d642d54c6bee5d7350f5150cdb28f44